查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1772267

美國心率管理設備市場規模、佔有率、趨勢分析報告：2025-2033年產品細分預測

U.S. Cardiac Rhythm Management Devices Market Size, Share & Trends Analysis Report By Product (Pacemakers, Defibrillators, Cardiac Resynchronization Therapy (CRT)), And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

預計 2024 年美國心率管理設備市場價值將達到 68 億美元，預計 2025 年至 2033 年的複合年成長率為 6.6%。

由於臨床需求不斷成長、設備技術不斷發展以及遠距遠端醫療日益融合，美國心率管理設備市場正在不斷發展變化。各公司正在根據這些變化調整其產品策略，重點關注小型化、連接性和持續監測，以支持急性和長期患者管理。

2024年5月，Defibtec在美國擴展了其Lifeline VIEW和ECG心臟去顫器產品線，推出了一款具有英語和西班牙語切換功能的雙語AED型號。這些更新旨在提高突發心臟緊急情況下不同急救人員的可及性和易用性。

在美國，心律不整和心臟衰竭的負擔日益加重，加速了心率管理設備的需求。人口老化加上高血壓、肥胖症和糖尿病等合併症的增加，對可靠的長期心臟介入措施的需求持續增加。心律調節器、心臟去顫器和再同步系統等設備正成為管理慢性心臟疾病和預防心臟性猝死的重要工具。 2024 年 9 月，加州大學舊金山分校的研究人員在《美國心臟病學會雜誌》上發表了一項研究，估計心房顫動影響 1,055 萬美國成年人。該分析基於 2005 年至 2019 年加州超過 2900 萬份醫院記錄，顯示目前的盛行率幾乎是先前估計值的三倍，並且正在影響更年輕、更多樣化的人群。

心臟衰竭是一種慢性、進行性疾病，患者心臟無法有效泵血，常導致住院治療、生活品質下降和高死亡率。心臟衰竭給醫療保健系統帶來沉重的負擔，尤其是在人口老化和糖尿病、高血壓等併發症日益增多的情況下。以設備為基礎的介入措施，例如心率管理設備和導線管理系統，對於心臟衰竭患者的早期診斷、穩定和長期照護越來越重要。根據美國心臟衰竭協會 2025 年 1 月的數據，美國約有 670 萬 20 歲及以上的成年人心臟衰竭，預計這一數字將在 2030 年達到 870 萬，2040 年達到 1030 萬，2050 年達到 1140 萬。

設備工程的進步正在再形成市場，尤其是無導線和無線技術的出現。無導線心律調節器減少了與傳統系統相關的併發症並簡化了嵌入型，而無線平台則改善了通訊和同步。這些增強功能提高了安全性、易用性和長期可靠性，使其在醫院和門診環境中都越來越有吸引力。 2025 年 4 月，Medtronic的Omnia Secure 獲得了 FDA 批准，這是一款專為植入式去心房顫動客製化的微型去心房顫動導線。其緊湊的 4.7 French 尺寸支持精確放置，同時降低了血管和瓣膜併發症的可能性。在 Heart Rhythm 2025 上發表的 LEADR 試驗結果報告了植入時去心房顫動完全成功。

遠端監控與心臟護理工作流程的整合正在推動醫療服務提供者的廣泛採用。嵌入型裝置的即時資料傳輸有助於及早發現心律不整和裝置效能問題，從而減少計劃外干預並支持主動護理模式。此功能也符合更廣泛的數位醫療策略，並符合支付方減少昂貴就診次數的利益。 2025年3月，MicroPort CRM獲得CE標誌核准，並在歐洲推出了其SmartView Connect行動應用。這款安卓應用程式將支援藍牙的心律調節器與診所連接起來，無需床邊監護儀即可對心搏過緩患者進行安全的遠端監控。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國心率管理設備市場變數、趨勢與範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國心率管理設備市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國心率管理設備市場：產品評估與趨勢分析

  • 美國心率管理設備市場：產品儀表板
  • 美國心率管理設備市場：產品差異分析
  • 美國心率管理設備市場（按產品和收益）
  • 心律調節器
    • 嵌入型
    • 體外
  • 心臟去顫器
    • 嵌入型心臟去顫器（ICD）
    • 體外心臟去顫器
  • 心臟再同步治療（CRT）
    • CRT心臟去顫器
    • CRT心律調節器

第5章 競爭態勢

  • 主要製造商的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • Key customers
    • Key company market share analysis, 2024
  • 公司簡介
    • Medtronic
    • Boston Scientific Corporation
    • Abbott
    • Schiller AG
    • Stryker
    • Koninklijke Philips NV
    • Biotronik
    • Progetti Srl
    • MicroPort Scientific Corporation
Product Code: GVR-4-68040-640-8

Market Size & Trends:

The U.S. cardiac rhythm management devices market size was estimated at USD 6.8 billion in 2024 and is projected to grow at a CAGR of 6.6% from 2025 to 2033. The U.S. cardiac rhythm management market is advancing through a convergence of growing clinical demand, evolving device technologies, and greater integration of remote care. Companies are aligning product strategies with these shifts, emphasizing miniaturization, connectivity, and continuous monitoring to support both acute and long-term patient management.

In May 2024, Defibtech expanded its Lifeline VIEW and ECG defibrillator lines in the U.S. by launching dual-language AED models with English and Spanish toggle features. These updates aim to improve accessibility and usability for diverse responders during sudden cardiac emergencies.

The increasing burden of arrhythmias and heart failure in the U.S. is accelerating the demand for cardiac rhythm management devices. An aging population combined with a rise in comorbidities such as hypertension, obesity, and diabetes is creating a steady need for reliable long-term cardiac interventions. Devices such as pacemakers, defibrillators, and resynchronization systems are becoming critical tools in managing chronic cardiac conditions and preventing sudden cardiac death. In September 2024, researchers from the University of California, San Francisco published a study in the Journal of the American College of Cardiology estimating that atrial fibrillation affects 10.55 million U.S. adults. The analysis, based on over 29 million hospital records in California from 2005-2019, revealed that current prevalence is nearly triple the earlier estimates and increasingly affects younger, more diverse populations.

Heart failure is a chronic, progressive condition marked by the heart's inability to pump blood effectively, often resulting in hospitalizations, reduced quality of life, and high mortality. It places a growing burden on healthcare systems, especially with aging populations and rising comorbidities such as diabetes and hypertension. Device-based interventions, including cardiac rhythm management and lead management systems, are increasingly essential for early diagnosis, stabilization, and long-term care in heart failure patients. In January 2025, according to the Heart Failure Society of America, around 6.7 million U.S. adults over 20 have heart failure, with prevalence projected to reach 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050.

Advances in device engineering are reshaping the market, particularly with the emergence of leadless and wireless technologies. Leadless pacemakers reduce complications associated with conventional systems and simplify implantation, while wireless platforms improve communication and synchronization. These enhancements offer greater safety, ease of use, and long-term reliability, making them increasingly attractive in both hospital and ambulatory settings. In April 2025, Medtronic gained FDA clearance for the OmniaSecure, a miniaturized defibrillation lead tailored for implantable cardioverter-defibrillator systems. Its compact 4.7 French size supports accurate placement while lowering the chance of vascular or valve complications. Findings from the LEADR trial, shared at Heart Rhythm 2025, reported full defibrillation success at implantation.

The integration of remote monitoring into cardiac care workflows is driving further adoption across healthcare providers. Real-time data transmission from implanted devices enables early detection of arrhythmias and device performance issues, reducing unplanned interventions and supporting proactive care models. This capability also aligns with broader digital health strategies and payer interest in minimizing costly hospital visits. In March 2025, MicroPort CRM launched the SmartView Connect App Mobile in Europe after receiving CE mark approval. The Android app links Bluetooth-enabled pacemakers to clinics, enabling secure remote monitoring without bedside monitors for bradycardia patients.

U.S. Cardiac Rhythm Management Devices Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 - 2033. For this study, Grand View Research has segmented the U.S. cardiac rhythm management devices market report based on product:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Pacemakers
    • Implantable
    • External
  • Defibrillators
    • Implantable Cardioverter Defibrillators (ICD)
    • S-ICD
    • T-ICD
    • External Defibrillator
    • Manual External Defibrillator
    • Automatic External Defibrillator
    • Wearable Cardioverter Defibrillator
  • Cardiac Resynchronization Therapy (CRT)
    • CRT-Defibrillator
    • CRT-Pacemakers

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Volume price analysis (Model 1)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Cardiac Rhythm Management Devices Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of arrhythmias and heart failure
      • 3.2.1.2. Advancements in leadless and wireless cardiac devices
      • 3.2.1.3. Integration of remote monitoring with cardiac care platforms
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Risk of device-related complications and recalls
      • 3.2.2.2. Stringent regulatory approvals and reimbursement challenges
  • 3.3. U.S. Cardiac Rhythm Management Devices Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Cardiac Rhythm Management Devices Market: Product Estimates & Trend Analysis

  • 4.1. U.S. Cardiac Rhythm Management Devices Market: Product Dashboard
  • 4.2. U.S. Cardiac Rhythm Management Devices Market: Product Movement Analysis
  • 4.3. U.S. Cardiac Rhythm Management Devices Market by Product, Revenue
  • 4.4. Pacemakers
    • 4.4.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.4.2. Implantable
      • 4.4.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.4.3. External
      • 4.4.3.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.5. Defibrillators
    • 4.5.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.5.2. Implantable Cardioverter Defibrillators (ICD)
      • 4.5.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
      • 4.5.2.2. S-ICD
        • 4.5.2.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
      • 4.5.2.3. T-ICD
        • 4.5.2.3.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.5.3. External Defibrillator
      • 4.5.3.1. Market estimates and forecast 2021 - 2033 (USD Million)
      • 4.5.3.2. Manual External Defibrillator
        • 4.5.3.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
      • 4.5.3.3. Automatic External Defibrillator
        • 4.5.3.3.1. Market estimates and forecast 2021 - 2033 (USD Million)
      • 4.5.3.4. Wearable Cardioverter Defibrillator
        • 4.5.3.4.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.6. Cardiac Resynchronization Therapy (CRT)
    • 4.6.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.6.2. CRT-Defibrillator
      • 4.6.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.6.3. CRT-Pacemaker
      • 4.6.3.1. Market estimates and forecast 2021 - 2033 (USD Million)

Chapter 5. Competitive Landscape

  • 5.1. Recent Developments & Impact Analysis, By Key Manufacturers
  • 5.2. Company/Competition Categorization
  • 5.3. Vendor Landscape
    • 5.3.1. List of key distributors and channel partners
    • 5.3.2. Key customers
    • 5.3.3. Key company market share analysis, 2024
  • 5.4. Company Profiles
    • 5.4.1. Medtronic
      • 5.4.1.1. Company overview
      • 5.4.1.2. Financial performance
      • 5.4.1.3. Product benchmarking
      • 5.4.1.4. Strategic initiatives
    • 5.4.2. Boston Scientific Corporation
      • 5.4.2.1. Company overview
      • 5.4.2.2. Financial performance
      • 5.4.2.3. Product benchmarking
      • 5.4.2.4. Strategic initiatives
    • 5.4.3. Abbott
      • 5.4.3.1. Company overview
      • 5.4.3.2. Financial performance
      • 5.4.3.3. Product benchmarking
      • 5.4.3.4. Strategic initiatives
    • 5.4.4. Schiller AG
      • 5.4.4.1. Company overview
      • 5.4.4.2. Financial performance
      • 5.4.4.3. Product benchmarking
      • 5.4.4.4. Strategic initiatives
    • 5.4.5. Stryker
      • 5.4.5.1. Company overview
      • 5.4.5.2. Financial performance
      • 5.4.5.3. Product benchmarking
      • 5.4.5.4. Strategic initiatives
    • 5.4.6. Koninklijke Philips N.V.
      • 5.4.6.1. Company overview
      • 5.4.6.2. Financial performance
      • 5.4.6.3. Product benchmarking
      • 5.4.6.4. Strategic initiatives
    • 5.4.7. Biotronik
      • 5.4.7.1. Company overview
      • 5.4.7.2. Financial performance
      • 5.4.7.3. Product benchmarking
      • 5.4.7.4. Strategic initiatives
    • 5.4.8. Progetti Srl
      • 5.4.8.1. Company overview
      • 5.4.8.2. Financial performance
      • 5.4.8.3. Product benchmarking
      • 5.4.8.4. Strategic initiatives
    • 5.4.9. MicroPort Scientific Corporation
      • 5.4.9.1. Company overview
      • 5.4.9.2. Financial performance
      • 5.4.9.3. Product benchmarking
      • 5.4.9.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 U.S. cardiac rhythm management devices market, by product, 2021 - 2033 (USD Million)
  • Table 3 Participant's overview
  • Table 4 Financial performance
  • Table 5 Key companies undergoing expansions
  • Table 6 Key companies undergoing acquisitions
  • Table 7 Key companies undergoing collaborations
  • Table 8 Key companies launching new services
  • Table 9 Key companies undergoing partnerships
  • Table 10 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 U.S. cardiac rhythm management devices market segmentation
  • Fig. 7 Market snapshot, 2024
  • Fig. 8 Market trends & outlook
  • Fig. 9 Market driver relevance analysis (current & future impact)
  • Fig. 10 Market restraint relevance analysis (current & future impact)
  • Fig. 11 Swot analysis, by factor (political & legal, economic, and technological)
  • Fig. 12 Porter's five forces analysis
  • Fig. 13 U.S. cardiac rhythm management devices market: Product Outlook Key Takeaways
  • Fig. 14 U.S. cardiac rhythm management devices market: Product Movement Analysis
  • Fig. 15 Pacemakers market, 2021 - 2033 (USD Million)
  • Fig. 16 Implantable pacemakers market, 2021 - 2033 (USD Million)
  • Fig. 17 External pacemakers market, 2021 - 2033 (USD Million)
  • Fig. 18 Defibrillators market, 2021 - 2033 (USD Million)
  • Fig. 19 Implantable cardioverter defibrillators (ICD) market, 2021 - 2033 (USD Million)
  • Fig. 20 S-ICD market, 2021 - 2033 (USD Million)
  • Fig. 21 T-ICD market, 2021 - 2033 (USD Million)
  • Fig. 22 External defibrillator market, 2021 - 2033 (USD Million)
  • Fig. 23 Manual external defibrillator market, 2021 - 2033 (USD Million)
  • Fig. 24 Automatic external defibrillator market, 2021 - 2033 (USD Million)
  • Fig. 25 Wearable cardioverter defibrillator market, 2021 - 2033 (USD Million)
  • Fig. 26 Cardiac resynchronization therapy (CRT) market, 2021 - 2033 (USD Million)
  • Fig. 27 CRT-defibrillator market, 2021 - 2033 (USD Million)
  • Fig. 28 CRT-pacemakers market, 2021 - 2033 (USD Million)
  • Fig. 29 Strategy framework